Consumer report on America’s Antibiotic Crisis 2015 has revealed that more than 8000 patients die each year due to MRSA infection and approximately 60,000 patients are sickened by it. Linezolid remains a standard treatment for MRSA infection. However, due to its high cost, the need for alternative has become apparent. A triple β-lactam combination i.e. Meropenem, Piperacillin and Tazobactam (ME/PI/TZ) was tested against highly resistant MRSA strain (23 diverse antibiotics) by NIH. It was found that this trio was acting synergistically and showing bactericidal action against MRSA. It also suppresses the evolution of resistance via reciprocal collateral sensitivity of MRSA constituents. A similar efficacy of this trio was also demonstrated as compared to Linezolid by performing a final test on MRSA infected mice for 6 days.
Source: National Chemical Biology. 2015, September 14. doi:10.1038/nchembio.1911
WorkSure a Contract Research Organization providing support to pharmaceutical, biotechnology and medical device industries.
![.jpg]( "JPG Image")
worksure.jpg (Size: 19.21 KB / Downloads: 1)
Source: National Chemical Biology. 2015, September 14. doi:10.1038/nchembio.1911
WorkSure a Contract Research Organization providing support to pharmaceutical, biotechnology and medical device industries.
worksure.jpg (Size: 19.21 KB / Downloads: 1)